Development of peptide-oligonucleotide hybrid biopolymers as flu type-independent affinity reagents
발표자
()
초록
내용
Emergence of viral diseases, such as COVID-19, is now regarded as a worldwide issue, because of their global spread and excess mortality all around the world. Especially, the frequent occurrence of viral mutations has attracted strong attention since previously developed vaccines and drugs were ineffective against the newly evolved viruses. In addressing the critical issue, we demonstrate the development of novel hybrid biopolymers, capable of simultaneously recognizing many kinds of influenza viruses. We found that regardless of genetic lineage and mutation, the influenza viruses share the common surface domains, of which access is sterically hindered by their cave-like indented locations. By redesigning a specific complementarity-determining region of antibody using molecular simulations, a minimal peptide was constructed to access one common domain of influenza viruses, and its optimal oligonucleotide scaffold was subsequently screened to create a flu type-independent affinity reagent.